Register for our free email digests:
Latest From Proacta Inc.
The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.
Following a setback earlier this year, the privately held Japanese bioventure LivTech has bounced back with a new deal for one of its main streams of research, signing an option agreement with Yakult Honsha for a series of novel anticancer antibodies.
Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.
- Therapeutic Areas
- Proacta Therapeutics Ltd.
- North America
- Parent & Subsidiaries
- Proacta Inc.
- Senior Management
John C Gutheil, MD, CEO
Kevin de la Torre, CFO
Terri J Melink, Dir., Clin. Dev.
- Contact Info
Phone: (858) 642-0386
4275 Executive Square
La Jolla, CA 92037
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.